Improved Pharma to Speak at 69th Annual Meeting of the American…

Lawyers Get Clients Today leftside

In this presentation, Dr. Byrn will discuss an overview of the current state of research and present some recent work conducted with our colleagues at Argonne National Laboratory and the University of Sao Paulo.

Improved Pharma LLC announces the upcoming presentation of “Continuity of Solids between Amorphous and Crystalline States – Insights from Synchrotron X-ray Pair Distribution (SXPDF) Studies”. The authors are Stephen R. Byrn and Pamela A. Smith of Improved Pharma, along with Chris Benmore of Argonne National Laboratory and Gabriel de Araujo of the University of Sao Paulo.

One of Improved Pharma’s key areas of research involves understanding the interactions present in amorphous drugs and drug:polymer dispersions. As pioneers in this area, they have worked with leading researchers to hone the experimental approach and also offer this service to their clients in the pharmaceutical industry.

To fully understand the structure of amorphous materials, Synchrotron X-ray Pair Distribution Function (SXPDF) is a powerful analytical tool. To stabilize an amorphous drug, one common approach is to formulate it as a drug:polymer dispersion. If the correct polymer is used at the correct loading, then intermolecular interactions between drug molecules are removed. Stated another way, domains of more than one drug molecule are not present. If the drug molecules are not in close contact with each other, then crystallization is inhibited and stability of the formulation increases. SXPDF allows one to detect and measure these interactions. For example, for pure amorphous preparations of lapatinib, SXPDF shows nearest neighbor contacts out to the 5th order. For compositions of lapatinib and the cellulosic polymer HPMC, only nearest neighbor contacts of the lapatinib molecules are present. For compositions of lapatinib and HPMCP (1:3) no nearest neighbor contacts of the lapatinib molecules are present indicating the lack of lapatinib domains. As expected, this last composition was the most stable indicating a correlation between the existence of domains and the tendency to crystallize.

In this presentation, Dr. Byrn will discuss an overview of the current state of research and present some recent work conducted with our colleagues at Argonne National Laboratory and the University of Sao Paulo. Calcium salts that form liquid crystals will also be discussed.

About Improved Pharma
Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Dr. Stephen Byrn and Sarah Byrn founded the company in 2006 after the successful acquisition of their first company, SSCI. Dr. Pamela Smith joined the company in 2018 after an 18-year tenure with SSCI. Improved Pharma offers services such as analytical testing, synchrotron-based formulation design, and expert consulting aiding the development and defense of intellectual property matters.

For more information about the techniques discussed in this article or about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

Share article on social media or email:

AdMedia 720×90 bottom